The role of permeability in drug ADME/PK, interactions and toxicity - Presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans

Pharmaceutical Research

Volumn 25, Issue 3, 2008, Pages 625-638

  Fagerholm, Urban ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Absorption; Classification system; Drug drug transport interactions; Permeability; Prediction

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; ATENOLOL; BETAXOLOL; CAFFEINE; CHLORAMPHENICOL; CIMETIDINE; CLONIDINE; DIGOXIN; DILTIAZEM; ENALAPRILAT; ETOPOSIDE; FEXOFENADINE; FLUNITRAZEPAM; HALOPERIDOL; HYDROCORTISONE; LOPERAMIDE; METHYLPREDNISOLONE; NADOLOL; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PINDOLOL; PRAVASTATIN; PROBENECID; QUINIDINE; SULPIRIDE; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE;

ANIMAL TISSUE; ARTICLE; ARTIFICIAL MEMBRANE; BILE FLOW; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION;

EID: 40549119872     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9397-y     Document Type: Article

References (82)

1. 1. U. Fagerholm D. Nilsson L. Knutson H. Lennernäs 1999 Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag Acta Physiol. Scand 165 315 324 10192182 10.1046/j.1365-201x.1999.00510.x 1:CAS:528:DyaK1MXitVejtbc%3D U. Fagerholm, D. Nilsson, L. Knutson, and H. Lennernäs. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. Acta Physiol. Scand. 165:315–324 (1999).
2. 2. U. Fagerholm. In Characteristics of intestinal permeability in humans in vivo and rats in situ. Doctoral thesis, Uppsala University, Sweden (1997).
3. 3. U. Fagerholm H. Lennernäs 1995 Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption Eur. J. Pharm. Sci 3 247 253 10.1016/0928-0987(95)00027-B 1:CAS:528:DyaK2MXoslGntL4%3D U. Fagerholm, and H. Lennernäs. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci. 3:247–253 (1995).
4. 4. Y. Shibata H. Takahashi M. Chiba Y. Ishii 2002 Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method Drug Met. Disp. 30 892 896 10.1124/dmd.30.8.892 1:CAS:528:DC%2BD38XlslWiu7s%3D Y. Shibata, H. Takahashi, M. Chiba, and Y. Ishii. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Met. Disp. 30:892–896 (2002).
5. 5. C. Y. Wu L. Benet 2005 Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res 22 11 23 15771225 10.1007/s11095-004-9004-4 1:CAS:528:DC%2BD2MXhtlCks70%3D C.-Y. Wu, and L. Benet. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22:11–23 (2005).
6. 6. U. Fagerholm 2007 Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS) J. Pharm. Pharmacol 59 751 757 17637167 10.1211/jpp.59.6.0001 1:CAS:528:DC%2BD2sXmtlKntL0%3D U. Fagerholm. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). J. Pharm. Pharmacol. 59:751–757 (2007).
7. 7. S. Willmann W. Schmitt J. Keldenich J. Lippert J. B. Dressman 2004 A physiological model for the estimation of the fraction dose absorbed in humans J. Med. Chem 47 4022 4031 15267240 10.1021/jm030999b 1:CAS:528:DC%2BD2cXlt1ymsL8%3D S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J. B. Dressman. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47:4022–4031 (2004).
8. 8. A. Goodman Gilman. In J. G. Hardman, L. E. Limbird, and A. Goodman Gilman (eds.) The pharmacological basis of therapeutics. McGraw-Hill (2001).
9. 9. R. S. Obach 1999 Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Met. Disp 27 1350 1359 1:CAS:528:DyaK1MXntFSht7c%3D R. S. Obach. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Met. Disp. 27:1350–1359 (1999).
10. 10. R. J. Riley D. F. McGinnity R. P. Austin 2005 A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes Drug Met. Disp 33 1304 1311 10.1124/dmd.105.004259 1:CAS:528:DC%2BD2MXpsFamt74%3D R. J. Riley, D. F. McGinnity, and R. P. Austin. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Met. Disp. 33:1304–1311 (2005).
11. 11. U. Fagerholm M. Johansson H. Lennernäs 1996 Comparison between permeability coefficients in rat and human jejunum Pharm. Res 13 1336 1342 8893271 10.1023/A:1016065715308 1:CAS:528:DyaK28XmtFWltLg%3D U. Fagerholm, M. Johansson, and H. Lennernäs. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1336–1342 (1996).
12. 12. W. L. Chiou P. W. Beuhler 2002 Comparison of oral absorption and bioavailability of drugs between monkey and human Pharm. Res 19 868 874 12134959 10.1023/A:1016169202830 1:CAS:528:DC%2BD38XltVSgtro%3D W. L. Chiou, and P. W. Beuhler. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm. Res. 19:868–874 (2002).
13. 13. J. Mordenti 1986 Man vs beast: pharmacokinetic scaling in mammals J. Pharm. Sci 75 1028 1040 3820096 10.1002/jps.2600751104 1:CAS:528:DyaL2sXmtVKisw%3D%3D J. Mordenti. Man vs beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028–1040 (1986).
14. 14. S. L. Lindstedt P. J. Schaeffer 2002 Use of allometry in predicting anatomical and physiological parameters of mammals Lab. Animals 36 1 19 10.1258/0023677021911731 1:CAS:528:DC%2BD38XitFyqsb4%3D S. L. Lindstedt, and P. J. Schaeffer. Use of allometry in predicting anatomical and physiological parameters of mammals. Lab. Animals. 36:1–19 (2002).
15. 15. R. W. Leggett L. R. Williams 1995 A proposed blood circulation model for reference man Health Physics 69 187 201 7622365 10.1097/00004032-199508000-00003 1:CAS:528:DyaK2MXntFGlsr4%3D R. W. Leggett, and L. R. Williams. A proposed blood circulation model for reference man. Health Physics. 69:187–201 (1995).
16. 16. M. Rowland, and T. N. Tozer. In Clinical pharmacokinetics: concepts and applications. M. Rowland and T.N. Tozer (eds.). Williams and Wilkins (1995).
17. 17. S. Lundquist M. Renftel J. Brillault L. Fenart R. Cecchelli M.-P. Dehouck 2002 Prediction of drug transport through the blood–brain barrier in vivo: a comparison between in vitro cell models Pharm. Res 19 976 981 12180550 10.1023/A:1016462205267 1:CAS:528:DC%2BD38Xltl2isLo%3D S. Lundquist, M. Renftel, J. Brillault, L. Fenart, R. Cecchelli, and M.-P. Dehouck. Prediction of drug transport through the blood–brain barrier in vivo: a comparison between in vitro cell models. Pharm. Res. 19:976–981 (2002).
18. 18. J. T. Goodwin D. E. Clark 2005 In silico predictions of blood–brain barrier penetration: considerations to “keep in mind” J. Pharmacol. Exp. Ther 315 477 483 15919767 10.1124/jpet.104.075705 1:CAS:528:DC%2BD2MXhtFyhsbbO J. T. Goodwin, and D. E. Clark. In silico predictions of blood–brain barrier penetration: Considerations to “keep in mind”. J. Pharmacol. Exp. Ther. 315:477–483 (2005).
19. 19. Y. Sawada M. Hanano Y. Sugiyama H. Harashima T. Iga 1984 Prediction of the volumes of distribution of basic drugs in humans based on data from animals J. Pharmacokin. Biopharm 12 587 596 10.1007/BF01059554 1:CAS:528:DyaL2MXitFCmu74%3D Y. Sawada, M. Hanano, Y. Sugiyama, H. Harashima, and T. Iga. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J. Pharmacokin. Biopharm. 12:587–596 (1984).
20. 20. Y. Sawada M. Hanano Y. Sugiyama T. Iga 1985 Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats J. Pharmacokin. Biopharm 13 477 492 10.1007/BF01059331 1:CAS:528:DyaL28Xhsl2ks7s%3D Y. Sawada, M. Hanano, Y. Sugiyama, and T. Iga. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J. Pharmacokin. Biopharm. 13:477–492 (1985).
21. 21. P. Poulin F.-P. Theil 2002 Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution J. Pharm. Sci 91 129 156 11782904 10.1002/jps.10005 1:CAS:528:DC%2BD38Xmslyhtg%3D%3D P. Poulin, and F.-P. Theil. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91:129–156 (2002).
22. 22. U. Fagerholm M. A. Björnsson 2005 Clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donating donator (CINOD) AZD3582 J. Pharm. Pharmacol 57 1539 1554 16354398 10.1211/jpp.57.12.0004 1:CAS:528:DC%2BD28Xit1Knu7o%3D U. Fagerholm, and M. A. Björnsson. Clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donating donator (CINOD) AZD3582. J. Pharm. Pharmacol. 57:1539–1554 (2005).
23. 23. J. B. Dressmann G. L. Amidon C. Reppas V. P. Shah 1998 Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms Pharm. Res 15 11 22 10.1023/A:1011984216775 J. B. Dressmann, G. L. Amidon, C. Reppas, and V. P. Shah. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15:11–22 (1998).
24. 24. D. Hörter J. B. Dressmann 2001 Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract Adv. Drug Del. Rev 46 75 87 10.1016/S0169-409X(00)00130-7 D. Hörter, and J. B. Dressmann. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Del. Rev. 46:75–87 (2001).
25. 25. A. Lindahl A.-L. Ungell L. Knutson H. Lennernäs 1997 Characterization of fluids from the stomach and proximal jejunum in men and women Pharm. Res 14 497 502 9144738 10.1023/A:1012107801889 1:CAS:528:DyaK2sXjtVWrsbk%3D A. Lindahl, A.-L. Ungell, L. Knutson, and H. Lennernäs. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14:497–502 (1997).
26. 26. B. Abrahamsson. In Biopharmaceutical aspects of extended release tablets based on the hydrophilic matrix principle. Doctoral thesis, Uppsala University, Sweden (1997).
27. 27. M. F. Paine D. D. Shen K. L. Kunze J. D. Perkins C. L. Marsh J. P. McVicar D. M. Barr B. S. Gillies K. E. Thummel 1996 First-pass metabolism of midazolam by the human small intestine Clin. Pharmacol. Ther 60 14 24 8689807 10.1016/S0009-9236(96)90162-9 1:CAS:528:DyaK28XltFSqurc%3D M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, C. L. Marsh, J. P. McVicar, D. M. Barr, B. S. Gillies, and K. E. Thummel. First-pass metabolism of midazolam by the human small intestine. Clin. Pharmacol. Ther. 60:14–24 (1996).
28. 28. T. Mizuma K. Kawashima S. Sakai S. Sakaguchi M. Hayashi 2005 Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans J. Pharm. Sci 94 571 575 15666320 10.1002/jps.20269 1:CAS:528:DC%2BD2MXisVWhsLo%3D T. Mizuma, K. Kawashima, S. Sakai, S. Sakaguchi, and M. Hayashi. Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans. J. Pharm. Sci. 94:571–575 (2005).
29. 29. L. Borgström L. Nyberg S. Jonsson C. Lindberg J. Paulson 1989 Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate Br. J. Clin. Pharmacol 27 49 56 2706188 L. Borgström, L. Nyberg, S. Jonsson, C. Lindberg, and J. Paulson. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br. J. Clin. Pharmacol. 27:49–56 (1989).
30. 30. I. Waziers De P. H. Cugnenc C. S. Yang J. P. Leroux P. H. Beaune 1990 Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues J. Pharmacol. Exp. Ther 253 387 394 2329521 I. De Waziers, P. H. Cugnenc, C. S. Yang, J. P. Leroux, and P. H. Beaune. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387–394 (1990).
31. 31. X. Cao S. T. Gibbs L. Fang H. A. Miller C. P. Landowski H.-C. Shin H. Lennernäs Y. Zhong G. L. Amidon L. X. Yu D. Sun 2006 Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model Pharm. Res 23 1675 1686 16841194 10.1007/s11095-006-9041-2 1:CAS:528:DC%2BD28XnvVyms7c%3D X. Cao, S. T. Gibbs, L. Fang, H. A. Miller, C. P. Landowski, H.-C.Shin, H. Lennernäs, Y. Zhong, G. L. Amidon, L. X. Yu, and D. Sun. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model? Pharm. Res. 23:1675–1686 (2006).
32. 32. E. G. Kerkhof van de A.-L. B. Ungell Å. K. Sjöberg M. H. Jager C. Hilgendorf I. A. M. Graaf de G. M. M. Groothuis 2006 Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations Drug Met. Disp 34 1893 1902 10.1124/dmd.106.011148 1:CAS:528:DC%2BD28XhtFGqt7nP E. G. van de Kerkhof, A.-L. B. Ungell, Å. K. Sjöberg, M. H. Jager, C. Hilgendorf, I. A. M. de Graaf, and G. M. M. Groothuis. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Met. Disp. 34:1893–1902 (2006).
33. 33. U. Fagerholm A. Lindahl H. Lennernäs 1997 Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms J. Pharm. Pharmacol 49 687 690 9255712 1:CAS:528:DyaK2sXkslWkt7Y%3D U. Fagerholm, A. Lindahl, and H. Lennernäs. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J. Pharm. Pharmacol. 49:687–690 (1997).
34. 34. S. S. Davis 1986 Evaluation of the gastrointestinal transit of pharmaceutical dosage forms using the technique of gammascintigraphy S.T.P Pharma 2 1015 1022 S. S. Davis. Evaluation of the gastrointestinal transit of pharmaceutical dosage forms using the technique of gammascintigraphy. S.T.P Pharma. 2:1015–1022 (1986).
35. 35. G. Alpini R. A. Garrick M. J. T. Jones R. Nunes N. Tavoloni 1986 Water and nonelectrolyte permeability of isolated rat hepatocytes Am. J. Physiol 251 C872 882 2431623 1:CAS:528:DyaL2sXmsVOrsQ%3D%3D G. Alpini, R. A. Garrick, M. J. T. Jones, R. Nunes, and N. Tavoloni. Water and nonelectrolyte permeability of isolated rat hepatocytes. Am. J. Physiol. 251:C872–882 (1986).
36. 36. A. Blouin. Morphometry of liver sinusoidal cells. In E. Wisse, Knook, D. L. (eds.) Kupffer Cells and Other Liver Sinusoidal Cells (1977).
37. 37. C. A. Goresky K. S. Pang A. J. Schwab F. Barker III W. F. Cherry G. G. Bach 1992 Uptake of a protein-bound polar compound, acetaminophen sulphate, by perfused rat liver Hepatol 16 173 190 10.1002/hep.1840160129 1:CAS:528:DyaK38XkvVart7Y%3D C. A. Goresky, K. S. Pang, A. J. Schwab, F. Barker III, W. F. Cherry, and G. G. Bach. Uptake of a protein-bound polar compound, acetaminophen sulphate, by perfused rat liver. Hepatol. 16:173–190 (1992).
38. 38. A. J. Schwab F. Barker III C. A. Goresky K. S. Pang 1990 Transfer of enalaprilat across rat liver cell membranes is barrier limited Am. J. Physiol 258 G461 475 2156443 1:CAS:528:DyaK3cXitFSmsrY%3D A. J. Schwab, F. Barker III, C. A. Goresky, and K. S. Pang. Transfer of enalaprilat across rat liver cell membranes is barrier limited. Am. J. Physiol. 258:G461–475 (1990).
39. 39. G. D. Mellick M. S. Roberts 1996 The disposition of aspirin and salicylic acid in the isolated perfused rat liver: The effect of normal and retrograde flow on availability and mean transit time J. Pharmacy Pharmacol 48 738 743 1:CAS:528:DyaK28XlsF2ktLg%3D G. D. Mellick, and M. S. Roberts. The disposition of aspirin and salicylic acid in the isolated perfused rat liver: The effect of normal and retrograde flow on availability and mean transit time. J. Pharmacy Pharmacol. 48:738–743 (1996).
40. 40. H. Boxenbaum 1980 Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin J. Pharmacokin. Biopharm 8 165 176 10.1007/BF01065191 1:CAS:528:DyaL3cXmtFGhtrw%3D H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokin. Biopharm. 8:165–176 (1980).
41. 41. E. R. Weibel W. Staubli H. R. Gnagi F. A. Hess 1969 Correlated morphometric and biochemical studies on the liver cell. Morphometric model, and normal morphometric data for rat liver J. Cell Biol 42 68 91 4891915 10.1083/jcb.42.1.68 1:CAS:528:DyaF1MXksFKls7w%3D E. R. Weibel, W. Staubli, H. R. Gnagi, and F. A. Hess. Correlated morphometric and biochemical studies on the liver cell. Morphometric model, and normal morphometric data for rat liver. J. Cell Biol. 42:68–91 (1969).
42. 42. P. J. Meier E. S. Sztul A. Reuben J. L. Boyer 1984 Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver J. Cell Biol 98 991 1000 6699096 10.1083/jcb.98.3.991 1:CAS:528:DyaL2cXhslWju7o%3D P. J. Meier, E. S. Sztul, A. Reuben, and J. L. Boyer. Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver. J. Cell Biol. 98:991–1000 (1984).
43. 43. TP-search transport database ( http://www.TP-search.jp/). Y. Sugiyama, H. Kusuhara, K. Maeda and Y. Nozaki (accessed 04/11/07).
44. 44. M. S. Roberts B. M. Magnusson F. J. Burczynski M. Weiss 2002 Enterohepatic circulation. Physiological, pharmacokinetic and clinical implications Clin. Pharmacokin 41 751 790 10.2165/00003088-200241100-00005 1:CAS:528:DC%2BD38XntFyru78%3D M. S. Roberts, B. M. Magnusson, F. J. Burczynski, and M. Weiss. Enterohepatic circulation. Physiological, pharmacokinetic and clinical implications. Clin. Pharmacokin. 41:751–790 (2002).
45. 45. D. Raušl N. Fotaki R. Zanoški M. Vertzoni B. Cetina-Èimek M. Z. I. Khan C. Reppas 2006 Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration J. Pharm. Pharmacol 58 827 836 16734984 10.1211/jpp.58.6.0013 1:CAS:528:DC%2BD28XpsFKgtLY%3D D. Raušl, N. Fotaki, R. Zanoški, M. Vertzoni, B. Cetina-Èimek, M. Z. I. Khan, and C. Reppas. Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. J. Pharm. Pharmacol. 58:827–836 (2006).
46. 46. Y. Shitara H. Sato Y. Sugiyama 2005 Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs Annu. Rev. Pharmacol.Toxicol 45 689 723 15822193 10.1146/annurev.pharmtox.44.101802.121444 1:CAS:528:DC%2BD2MXisVWjtbw%3D Y. Shitara, H. Sato, and Y. Sugiyama. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol.Toxicol. 45:689–723 (2005).
47. 47. R. Masereeuw F. G. M. Russel 2001 Mechanisms and clinical implications of renal drug excretion Drug Met. Rev 33 299 351 10.1081/DMR-120000654 1:CAS:528:DC%2BD38XjvVGqsw%3D%3D R. Masereeuw, and F. G. M. Russel. Mechanisms and clinical implications of renal drug excretion. Drug Met. Rev. 33:299–351 (2001).
48. 48. J. D. Irvine L. Takahashi K. Lackhart J. Cheong J. W. Tolan H. E. Selick J. R. Grove 1999 MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening J. Pharm. Sci 88 29 33 10.1021/js9803205 J. D. Irvine, L. Takahashi, K. Lackhart, J. Cheong, J. W. Tolan, H. E. Selick, and J. R. Grove. MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88:29–33 (1999).
49. 49. M. Rowland, and T. N. Tozer. In Clinical pharmacokinetics: concepts and applications. Lea and Febiger (1989).
50. 50. H. Waterbeemd van de G. Camenisch G. Folkers J. R. Chretien O. A. Raevsky 1998 Estimation of blood–brain barrier crossing of drugs using molecular size and shape, and h-bonding descriptors J. Drug Targ 6 151 165 10.3109/10611869808997889 H. van de Waterbeemd, G. Camenisch, G. Folkers, J. R. Chretien, and O. A. Raevsky. Estimation of blood–brain barrier crossing of drugs using molecular size and shape, and h-bonding descriptors. J. Drug Targ. 6:151–165 (1998).
51. 51. J. Kelder P. D. J. Grootenhuis D. M. Bayada L. P. C. Delbressine J.-P. Ploemen 1999 Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res 16 1514 1519 10554091 10.1023/A:1015040217741 1:CAS:528:DyaK1MXntVOhtb8%3D J. Kelder, P. D. J. Grootenhuis, D. M. Bayada, L. P. C. Delbressine, and J.-P. Ploemen. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16:1514–1519 (1999).
52. 52. W. M. Pardridge 2003 Blood–brain barrier drug targeting: the future of brain drug development Molec. Intervent 3 90 105 10.1124/mi.3.2.90 1:CAS:528:DC%2BD3sXjsVWhsrk%3D W. M. Pardridge. Blood–brain barrier drug targeting: the future of brain drug development. Molec. Intervent. 3:90–105 (2003).
53. 53. W. P. Pardridge 2005 The blood–brain barrier: bottleneck in brain drug development NeuroRx 2 3 14 15717053 10.1602/neurorx.2.1.3 W. P. Pardridge. The blood–brain barrier: bottleneck in brain drug development. NeuroRx. 2:3–14 (2005).
54. 54. D. J. Begley 1996 The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system J. Pharm. Pharmacol 48 136 146 8935161 1:CAS:528:DyaK28XisFGlsb0%3D D. J. Begley. The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48:136–146 (1996).
55. 55. T. J. Abbruscato S. A. Thomas V. J. Hruby T. P. Davis 1997 Blood–brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: comparison with morphine J. Pharmacol. Exp. Ther 280 402 409 8996221 1:CAS:528:DyaK2sXntFOitg%3D%3D T. J. Abbruscato, S. A. Thomas, V. J. Hruby, and T. P. Davis. Blood–brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther. 280:402–409 (1997).
56. 56. J. Kawakami K. Yamamoto Y. Sawada T. Iga 1994 Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data J. Pharmacokin. Biopharm 22 207 227 10.1007/BF02353329 1:CAS:528:DyaK2MXjsVams7Y%3D J. Kawakami, K. Yamamoto, Y. Sawada, and T. Iga. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J. Pharmacokin. Biopharm. 22:207–227 (1994).
57. 57. S. Syvänen G. Blomquist M. Sprycha A. U. Höglund M. Roman O. Eriksson M. Hammarlund-Udenaes B. Långström M. Bergström 2006 Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET NeuroImage 32 1134 1141 16857389 10.1016/j.neuroimage.2006.05.047 S. Syvänen, G. Blomquist, M. Sprycha, A. U. Höglund, M. Roman, O. Eriksson, M. Hammarlund-Udenaes, B. Långström, and M. Bergström. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET. NeuroImage. 32:1134–1141 (2006).
58. 58. J. Asperen van U. Mayer O. Tellingen van J. H. Beijnen 1997 The functional role of P-glycoprotein in the blood–brain barrier J. Pharm. Sci 86 881 884 9269863 10.1021/js9701364 J. van Asperen, U. Mayer, O. van Tellingen, and J. H. Beijnen. The functional role of P-glycoprotein in the blood–brain barrier. J. Pharm. Sci. 86:881–884 (1997).
59. 59. D. E. Clark 1999 Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood–brain barrier penetration J. Pharm. Sci 88 815 821 10430548 10.1021/js980402t 1:CAS:528:DyaK1MXjvFGitbk%3D D. E. Clark. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood–brain barrier penetration. J. Pharm. Sci. 88:815–821 (1999).
60. 60. I. Tamai A. Tsuji 2000 Transporter-mediated permeation of drugs across the blood–brain barrier J. Pharm. Sci 11 1371 1388 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D I. Tamai, and A. Tsuji. Transporter-mediated permeation of drugs across the blood–brain barrier. J. Pharm. Sci. 11:1371–1388 (2000).
61. 61. V. Berezowski C. Landry S. Lundquist L. Dehouck R. Cecchelli M. P. Dehouck L. Fenart 2004 Transport of drug cocktails through an in vitro blood–brain barrier: is it a good strategy for increasing the throughput of the discovery pipeline Pharm. Res 21 756 760 15180330 10.1023/B:PHAM.0000026424.78528.11 1:CAS:528:DC%2BD2cXjs1Kisro%3D V. Berezowski, C. Landry, S. Lundquist, L. Dehouck, R. Cecchelli, M. P. Dehouck, and L. Fenart. Transport of drug cocktails through an in vitro blood–brain barrier: is it a good strategy for increasing the throughput of the discovery pipeline? Pharm. Res. 21:756–760 (2004).
62. 62. S. A. Thomas T. J. Abbruscato V. S. Hau T. J. Gillespie J. Zsigo V. J. Hruby T. P. Davis 1997 Structure-activity relationships of a series of [ d-Ala 2 ]deltorphin I and II analogues; in vitro blood–brain barrier permeability and stability J. Pharmacol. Exp. Ther 281 817 825 9152390 1:CAS:528:DyaK2sXjtFyns7w%3D S. A. Thomas, T. J. Abbruscato, V. S. Hau, T. J. Gillespie, J. Zsigo, V. J. Hruby, and T. P. Davis. Structure-activity relationships of a series of [ d-Ala 2 ]deltorphin I and II analogues; in vitro blood–brain barrier permeability and stability. J. Pharmacol. Exp. Ther. 281:817–825 (1997).
63. 63. A. Kakee T. Terasaki Y. Sugiyama 1996 Brain efflux index as a novel method of analyzing efflux transport at the blood–brain barrier J. Pharmacol. Exp. Ther 277 1550 1559 8667222 1:CAS:528:DyaK28XjslGltbc%3D A. Kakee, T. Terasaki, and Y. Sugiyama. Brain efflux index as a novel method of analyzing efflux transport at the blood–brain barrier. J. Pharmacol. Exp. Ther. 277:1550–1559 (1996).
64. 64. M.-P. Dehouck R. Cecchelli A. R. Green M. Renftel S. Lundquist 2002 In vitro blood–brain barrier permeability and cerebral endothelial cell uptake if the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions Brain Res 955 229 235 12419541 10.1016/S0006-8993(02)03469-8 1:CAS:528:DC%2BD38Xotl2itb8%3D M.-P. Dehouck, R. Cecchelli, A. R. Green, M. Renftel, and S. Lundquist. In vitro blood–brain barrier permeability and cerebral endothelial cell uptake if the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res. 955:229–235 (2002).
65. 65. H. Fischer R. Gottschlich A. Seelig 1998 Blood–brain barrier permeation: molecular parameters governing passive diffusion J. Membr. Biol 165 201 211 9767674 10.1007/s002329900434 1:CAS:528:DyaK1cXmsFOlsL4%3D H. Fischer, R. Gottschlich, and A. Seelig. Blood–brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 165:201–211 (1998).
66. 66. J. Karlsson P. Artursson 1992 A new diffusion chamber system for the determination of drug permeability coefficients across the human intestinal epithelium that are independent on the unstirred water layer Biochim. Biophys. Acta 1111 204 210 1420256 10.1016/0005-2736(92)90312-A 1:CAS:528:DyaK3sXltFOlsw%3D%3D J. Karlsson, and P. Artursson. A new diffusion chamber system for the determination of drug permeability coefficients across the human intestinal epithelium that are independent on the unstirred water layer. Biochim. Biophys. Acta. 1111:204–210 (1992).
67. 67. Y. Su P. J. Sinko 2006 Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it Expert Opin. Drug Del 3 419 435 10.1517/17425247.3.3.419 1:CAS:528:DC%2BD28Xkt12gsb8%3D Y. Su, and P. J. Sinko. Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it? Expert Opin. Drug Del. 3:419–435 (2006).
68. 68. E. Boström U. S. H. Simonsson M. Hammarlund-Udenaes 2006 In vivo blood–brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics Drug Met. Disp 34 1624 1631 10.1124/dmd.106.009746 1:CAS:528:DC%2BD28Xpt1Sksb4%3D E. Boström, U. S. H. Simonsson, and M. Hammarlund-Udenaes. In vivo blood–brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Met. Disp. 34:1624–1631 (2006).
69. 69. H. Lennernäs 1997 Human jejunal effective permeability and its correlation with preclinical drug absorption models J. Pharm. Pharmacol 49 627 638 9255703 H. Lennernäs. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 49:627–638 (1997).
70. 70. D. K. Hansen D. O. Scott K. W. Otis S. M. Lunte 2002 Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling J. Pharmaceut. Biomed. Anal 27 945 958 10.1016/S0731-7085(01)00542-8 1:CAS:528:DC%2BD38XhtVKktrg%3D D. K. Hansen, D. O. Scott, K. W. Otis, and S. M. Lunte. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J. Pharmaceut. Biomed. Anal. 27:945–958 (2002).
71. 71. L. S. Schanker P. A. Nafpliotis J. M. Johnson 1961 Passage of organic bases into human red cells J. Pharmacol. Ther 133 325 331 1:CAS:528:DyaF3MXhtlaktbc%3D L. S. Schanker, P. A. Nafpliotis, and J. M. Johnson. Passage of organic bases into human red cells. J. Pharmacol. Ther. 133:325–331 (1961).
72. 72. P. Naccache R. I. Sha’afi 1973 Patterns of nonelectrolyte permeability in human red blood cell membrane J. Gen. Physiol 62 714 736 4804758 10.1085/jgp.62.6.714 1:CAS:528:DyaE2cXks1WqtA%3D%3D P. Naccache, and R. I. Sha’afi. Patterns of nonelectrolyte permeability in human red blood cell membrane. J. Gen. Physiol. 62:714–736 (1973).
73. 73. R. Sandström A. Karlsson L. Knutson H. Lennernäs 1998 Jejunal absorption and metabolism of R/S-verapamil in humans Pharm. Res 15 856 862 9647350 10.1023/A:1011916329863 R. Sandström, A. Karlsson, L. Knutson, and H. Lennernäs. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15:856–862 (1998).
74. 74. A. Tsuji I. Tamai 1997 Blood–brain barrier function of P-glycoprotein Adv. Drug Del. Rev 25 287 298 10.1016/S0169-409X(97)00504-8 1:CAS:528:DyaK2sXjsVKht7k%3D A. Tsuji, and I. Tamai. Blood–brain barrier function of P-glycoprotein. Adv. Drug Del. Rev. 25:287–298 (1997).
75. 75. A. J. M. Sadeque C. Wandel H. He S. Shah A. J. J. Wood 2000 Increased drug delivery to the brain by P-glycoprotein inhibition Clin. Pharmacol. Ther 68 231 237 11014404 10.1067/mcp.2000.109156 1:CAS:528:DC%2BD3cXntFOgtb8%3D A. J. M. Sadeque, C. Wandel, H., He, S. Shah, and A. J. J. Wood. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:231–237 (2000).
76. 76. S. Hirata S. Izumi S. T. Furukubo M. Ota M. Fujita T. Yamakawa I. Hasegawa H. Ohtani Y. Sawada 2005 Int. J. Clin. Pharmacol. Ther 43 30 36 15704612 1:CAS:528:DC%2BD2MXhtVSrtrY%3D S. Hirata, S. Izumi, S. T. Furukubo, M. Ota, M. Fujita, T. Yamakawa, I. Hasegawa, H. Ohtani, and Y. Sawada. Int. J. Clin. Pharmacol. Ther. 43:30–36 (2005).
77. 77. J. Rengelshausen C. Goggelmann J. Burhenne K. D. Reidel J. Ludwig J. Weiss G. Mikus I. Walter-Sack W. E. Haefeli 2003 Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction Br. J. Clin. Pharmacol 56 32 38 12848773 10.1046/j.1365-2125.2003.01824.x 1:CAS:528:DC%2BD3sXmvFSls7w%3D J. Rengelshausen, C. Goggelmann, J. Burhenne, K. D. Reidel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack, and W. E. Haefeli. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction. Br. J. Clin. Pharmacol. 56:32–38 (2003).
78. 78. R. H. Ho R. B. Kim 2005 Transporters and drug therapy: implications for drug disposition and disease Clin. Pharmacol. Ther 78 260 277 16153397 10.1016/j.clpt.2005.05.011 1:CAS:528:DC%2BD2MXpvV2rt78%3D R. H. Ho, and R. B. Kim. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78:260–277 (2005).
79. 79. FASS web-site http://www.fass.se.
80. 80. G. A. Siebert D. Y. Hung P. Chang M. S. Roberts 2004 Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs J. Pharmacol. Exp. Ther 308 228 235 14566005 10.1124/jpet.103.056770 1:CAS:528:DC%2BD2cXmsFegtw%3D%3D G. A. Siebert, D. Y. Hung, P. Chang, and M. S. Roberts. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J. Pharmacol. Exp. Ther. 308:228–235 (2004).
81. 81. U. Fagerholm M. Johansson H. Lennern 1996 Comparison between permeability coefficients in rat and human jejunum Pharm. Res. 13 1336 1342 8893271 10.1023/A:1016065715308 1:CAS:528:DyaK28XmtFWltLg%3D U. Fagerholm, M. Johansson, and H. Lennern. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1336–1342 (1996).
82. 82. U. Fagerholm 2007 Prediction of human pharmacokinetics-Gastrointestinal absorption J. Pharm. Pharmacol. 59 905 916 17637184 10.1211/jpp.59.7.0001 1:CAS:528:DC%2BD2sXntl2gs7w%3D U. Fagerholm. Prediction of human pharmacokinetics-Gastrointestinal absorption. J. Pharm. Pharmacol. 59:905–916 (2007).